These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 12538456)

  • 1. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
    Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
    Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
    Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
    Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis.
    Gu J; Zhang L; Swisher SG; Liu J; Roth JA; Fang B
    Oncogene; 2004 Feb; 23(6):1300-7. PubMed ID: 14676844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
    Roth JA; Swisher SG; Merritt JA; Lawrence DD; Kemp BL; Carrasco CH; El-Naggar AK; Fossella FV; Glisson BS; Hong WK; Khurl FR; Kurie JM; Nesbitt JC; Pisters K; Putnam JB; Schrump DS; Shin DM; Walsh GL
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):33-7. PubMed ID: 9704675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
    Cunningham CC; Chada S; Merritt JA; Tong A; Senzer N; Zhang Y; Mhashilkar A; Parker K; Vukelja S; Richards D; Hood J; Coffee K; Nemunaitis J
    Mol Ther; 2005 Jan; 11(1):149-59. PubMed ID: 15585416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
    Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
    J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro.
    Saeki T; Mhashilkar A; Chada S; Branch C; Roth JA; Ramesh R
    Gene Ther; 2000 Dec; 7(23):2051-7. PubMed ID: 11175318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
    Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
    Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts.
    Qin M; Chen S; Yu T; Escuadro B; Sharma S; Batra RK
    Clin Cancer Res; 2003 Oct; 9(13):4992-9. PubMed ID: 14581374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
    Tong AW; Nemunaitis J; Su D; Zhang Y; Cunningham C; Senzer N; Netto G; Rich D; Mhashilkar A; Parker K; Coffee K; Ramesh R; Ekmekcioglu S; Grimm EA; van Wart Hood J; Merritt J; Chada S
    Mol Ther; 2005 Jan; 11(1):160-72. PubMed ID: 15585417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
    Fujiwara T; Tanaka N; Kanazawa S; Ohtani S; Saijo Y; Nukiwa T; Yoshimura K; Sato T; Eto Y; Chada S; Nakamura H; Kato H
    J Clin Oncol; 2006 Apr; 24(11):1689-99. PubMed ID: 16505415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms.
    Kawabe S; Nishikawa T; Munshi A; Roth JA; Chada S; Meyn RE
    Mol Ther; 2002 Nov; 6(5):637-44. PubMed ID: 12409262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
    Zhang SW; Xiao SW; Liu CQ; Sun Y; Su X; Li DM; Xu G; Zhu GY; Xu B
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):426-8. PubMed ID: 16188130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan].
    Kagawa S; Fujiwara T; Tanaka N
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):193-7. PubMed ID: 12610865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
    Kandioler D; Stamatis G; Eberhardt W; Kappel S; Zöchbauer-Müller S; Kührer I; Mittlböck M; Zwrtek R; Aigner C; Bichler C; Tichy V; Hudec M; Bachleitner T; End A; Müller MR; Roth E; Klepetko W
    J Thorac Cardiovasc Surg; 2008 May; 135(5):1036-41. PubMed ID: 18455581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
    Oakley R; Phillips E; Hooper R; Wilson D; Partridge M
    Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New horizons: gene therapy for cancer.
    Baselga J
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S39-42. PubMed ID: 10630368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).
    Yen N; Ioannides CG; Xu K; Swisher SG; Lawrence DD; Kemp BL; El-Naggar AK; Cristiano RJ; Fang B; Glisson BS; Hong WK; Khuri FR; Kurie JM; Lee JJ; Lee JS; Merritt JA; Mukhopadhyay T; Nesbitt JC; Nguyen D; Perez-Soler R; Pisters KM; Putnam JB; Schrump DS; Shin DM; Walsh GL; Roth JA
    Cancer Gene Ther; 2000 Apr; 7(4):530-6. PubMed ID: 10811470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.